JHL Biotech Inc., of Hsinchu, Taiwan, said it submitted a phase I clinical trial application to European authorities for its proposed bevacizumab biosimilar, JHL-1149. The company is planning to conduct a single-site, three-arm pharmacokinetic study in healthy volunteers in Sofia, Bulgaria, beginning March 2018. Read More

PERTH, Australia – Unlike its Australian peers, regenerative medicine company Regeneus Ltd. is not focusing on the U.S. market. Instead, it's placing its bets on Japan first and then will move out to other territories. Read More

HONG KONG – Caywon Pharmaceutical Group Ltd. is using Crowd Machine technology to become one of the first companies in China to specialize in decentralizing the pharmaceuticals development process. Read More

An estimated one-third of the world's population is infected with tuberculosis, with active infections typically emerging in the most vulnerable populations such as those with HIV, malnutrition or diabetes. It's one of the most common bacterial infections – and is among the most common causes of death worldwide, second only to HIV/AIDS as a deadly infectious disease. Read More

PERTH, Australia – After years of consultations and pressure from industry, Australia's Therapeutic Goods Administration (TGA) will finally begin regulating autologous cell and tissue products as biologicals. Read More